Etanercept Biosimilar SDZ ETN Demonstrates Efficacy, Safety in Rheumatic Disease

Patients with rheumatic disease treated with biosimilar SDZ ETN reported high treatment persistence at month 12 as well as comparable safety and efficacy.

Related Keywords

Munich ,Bayern ,Germany ,Docus Herbert Kellner ,Herbert Kellner ,Department Of Rheumatology ,Neuwittelsbach Hospital ,Disease Activity Score ,Erythrocyte Sedimentation Rate ,